Comparison of Different Treatment Modalities Outcomes in
Clinically Node-positive Bladder Cancer: Analysis of a
Population-based Cancer Registry

J 2019

Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry

STANÍK, Michal, Alexandr POPRACH, Michaela ZAPLETALOVÁ, Denisa KREJČÍ, Daniel MACIK et. al.

Základní údaje

Originální název

Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry

Autoři

STANÍK, Michal (703 Slovensko, garant), Alexandr POPRACH (203 Česká republika), Michaela ZAPLETALOVÁ (203 Česká republika, domácí), Denisa KREJČÍ (203 Česká republika, domácí), Daniel MACIK (203 Česká republika), Ivo CAPAK (203 Česká republika), Jiří JARKOVSKÝ (203 Česká republika, domácí), Radek LAKOMY (203 Česká republika) a Jan DOLEZEL (203 Česká republika)

Vydání

CLINICAL GENITOURINARY CANCER, DALLAS, CIG MEDIA GROUP, LP, 2019, 1558-7673

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.695

Kód RIV

RIV/00216224:14110/19:00111954

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.clgc.2019.04.007

UT WoS

000476618100006

Klíčová slova anglicky

Chemotherapy; Combined modality therapy; Cystectomy; Lymphadenopathy; Urinary bladder neoplasms

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 1. 2020 12:10, Mgr. Tereza Miškechová

Anotace

V originále

Recently, a few retrospective studies demonstrated a potential benefit of multimodal therapy in patients with clinically node-positive bladder cancer. We assessed the efficacy of different treatment modalities in 661 patients (cTanyN1-3M0) identified from the Czech National Cancer Registry. When compared with chemotherapy, combined treatment integrating cystectomy and perioperative chemotherapy reduced the risk of overall mortality by 21% and may lead to a long-term survival in one-quarter of patients. Introduction: Patients with clinically node-positive bladder cancer were historically considered to have uniformly poor prognosis and were frequently treated with palliative chemotherapy (CHT) only. Although retrospective data show that long-term survival with combined treatment (surgery + CHT) is possible in one-third of these patients, consensus on a treatment algorithm is still lacking. The aim of the study is to compare the efficacy of different treatment modalities based on data from a population-based cancer registry. Patients and Methods: The study comprises 661 patients identified from the Czech National Cancer Registry (1996-2015) with cTanyN1-3M0 bladder cancer; 195 were treated with CHT alone, 234 underwent radical cystectomy alone (RC), and 232 received a combination of RC and perioperative CHT (RC + CHT). Multivariate Cox proportional hazard regression analyses were used to evaluate the effectiveness of various treatments. Results: The 5-year OS for CHT alone, RC alone, and RC + CHT were 21.7% (95% confidence interval [CI], 15.4%-28.0%), 12.1% (95% CI, 7.4%-16.7%), and 25.4% (95% CI, 18.9%-31.9%), respectively (P < .001). The median survivals were 17, 10, and 23 months, respectively. In multivariate analysis, age > 60 years (hazard ratio, 1.29; 95% CI, 1.06-1.56; P = .011) and clinical stage cT3-4 (hazard ratio, 1.39; 95% CI, 1.12-1.71; P = .002) were negative predictors of survival. When compared with CHT, RC + CHT reduced the risk of overall mortality by 21% (P = .044). Conclusion: Approximately one-quarter of clinically node-positive patients may achieve long-term survival with combined treatment integrating RC and perioperative CHT. The overall survival of patients is significantly improved with a multimodal approach in comparison to CHT alone. (C) 2019 Elsevier Inc. All rights reserved.

Citovat

STANÍK, Michal, Alexandr POPRACH, Michaela ZAPLETALOVÁ, Denisa KREJČÍ, Daniel MACIK, Ivo CAPAK, Jiří JARKOVSKÝ, Radek LAKOMY a Jan DOLEZEL. Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry. CLINICAL GENITOURINARY CANCER. DALLAS: CIG MEDIA GROUP, LP, 2019, roč. 17, č. 4, s. "E759"-"E767", 9 s. ISSN 1558-7673. Dostupné z: https://dx.doi.org/10.1016/j.clgc.2019.04.007.

@article{1597539,
   author = {Staník, Michal and Poprach, Alexandr and Zapletalová, Michaela and Krejčí, Denisa and Macik, Daniel and Capak, Ivo and Jarkovský, Jiří and Lakomy, Radek and Dolezel, Jan},
   article_location = {DALLAS},
   article_number = {4},
   doi = {http://dx.doi.org/10.1016/j.clgc.2019.04.007},
   keywords = {Chemotherapy; Combined modality therapy; Cystectomy; Lymphadenopathy; Urinary bladder neoplasms},
   language = {eng},
   issn = {1558-7673},
   journal = {CLINICAL GENITOURINARY CANCER},
   title = {Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry},
   url = {http://dx.doi.org/10.1016/j.clgc.2019.04.007},
   volume = {17},
   year = {2019}
}

TY  - JOUR
ID  - 1597539
AU  - Staník, Michal - Poprach, Alexandr - Zapletalová, Michaela - Krejčí, Denisa - Macik, Daniel - Capak, Ivo - Jarkovský, Jiří - Lakomy, Radek - Dolezel, Jan
PY  - 2019
TI  - Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry
JF  - CLINICAL GENITOURINARY CANCER
VL  - 17
IS  - 4
SP  - "E759"-"E767"
EP  - "E759"-"E767"
PB  - CIG MEDIA GROUP, LP
SN  - 15587673
KW  - Chemotherapy
KW  - Combined modality therapy
KW  - Cystectomy
KW  - Lymphadenopathy
KW  - Urinary bladder neoplasms
UR  - http://dx.doi.org/10.1016/j.clgc.2019.04.007
L2  - http://dx.doi.org/10.1016/j.clgc.2019.04.007
N2  - Recently, a few retrospective studies demonstrated a potential benefit of multimodal therapy in patients with clinically node-positive bladder cancer. We assessed the efficacy of different treatment modalities in 661 patients (cTanyN1-3M0) identified from the Czech National Cancer Registry. When compared with chemotherapy, combined treatment integrating cystectomy and perioperative chemotherapy reduced the risk of overall mortality by 21% and may lead to a long-term survival in one-quarter of patients. Introduction: Patients with clinically node-positive bladder cancer were historically considered to have uniformly poor prognosis and were frequently treated with palliative chemotherapy (CHT) only. Although retrospective data show that long-term survival with combined treatment (surgery + CHT) is possible in one-third of these patients, consensus on a treatment algorithm is still lacking. The aim of the study is to compare the efficacy of different treatment modalities based on data from a population-based cancer registry. Patients and Methods: The study comprises 661 patients identified from the Czech National Cancer Registry (1996-2015) with cTanyN1-3M0 bladder cancer; 195 were treated with CHT alone, 234 underwent radical cystectomy alone (RC), and 232 received a combination of RC and perioperative CHT (RC + CHT). Multivariate Cox proportional hazard regression analyses were used to evaluate the effectiveness of various treatments. Results: The 5-year OS for CHT alone, RC alone, and RC + CHT were 21.7% (95% confidence interval [CI], 15.4%-28.0%), 12.1% (95% CI, 7.4%-16.7%), and 25.4% (95% CI, 18.9%-31.9%), respectively (P < .001). The median survivals were 17, 10, and 23 months, respectively. In multivariate analysis, age > 60 years (hazard ratio, 1.29; 95% CI, 1.06-1.56; P = .011) and clinical stage cT3-4 (hazard ratio, 1.39; 95% CI, 1.12-1.71; P = .002) were negative predictors of survival. When compared with CHT, RC + CHT reduced the risk of overall mortality by 21% (P = .044). Conclusion: Approximately one-quarter of clinically node-positive patients may achieve long-term survival with combined treatment integrating RC and perioperative CHT. The overall survival of patients is significantly improved with a multimodal approach in comparison to CHT alone. (C) 2019 Elsevier Inc. All rights reserved.
ER  -

STANÍK, Michal, Alexandr POPRACH, Michaela ZAPLETALOVÁ, Denisa KREJČÍ, Daniel MACIK, Ivo CAPAK, Jiří JARKOVSKÝ, Radek LAKOMY a Jan DOLEZEL. Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry. \textit{CLINICAL GENITOURINARY CANCER}. DALLAS: CIG MEDIA GROUP, LP, 2019, roč.~17, č.~4, s.~''E759''-''E767'', 9 s. ISSN~1558-7673. Dostupné z: https://dx.doi.org/10.1016/j.clgc.2019.04.007.

Podrobný výpis o publikaci